{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:51:47Z","timestamp":1774270307479,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:00:00Z","timestamp":1615680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:00:00Z","timestamp":1615680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12328-021-01384-9","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T13:02:35Z","timestamp":1615726955000},"page":"988-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Isolated adrenocorticotropic hormone deficiency induced by nivolumab treatment for advanced gastric cancer"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-404X","authenticated-orcid":false,"given":"Tsutomu","family":"Namikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichro","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Fukudome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Munekage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Hanazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,14]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s00595-020-02048-w","volume":"50","author":"T Namikawa","year":"2020","unstructured":"Namikawa T, Yokota K, Tanioka N, et al. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 2020;50:1486\u201395.","journal-title":"Surg Today"},{"key":"1384_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/annonc\/mdy041","volume":"29","author":"EE Vokes","year":"2018","unstructured":"Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29:959\u201365.","journal-title":"Ann Oncol"},{"key":"1384_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101\u201312.","journal-title":"Gastric Cancer"},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1\u201319.","journal-title":"Gastric Cancer"},{"key":"1384_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138.","journal-title":"Ann Oncol"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.14740\/jocmr3257w","volume":"10","author":"K Takebayashi","year":"2018","unstructured":"Takebayashi K, Ujiie A, Kubo M, et al. Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res. 2018;10:358\u201362.","journal-title":"J Clin Med Res"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"e8426","DOI":"10.1097\/MD.0000000000008426","volume":"96","author":"MF Zeng","year":"2017","unstructured":"Zeng MF, Chen LL, Ye HY, et al. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Med (Baltim). 2017;96:e8426.","journal-title":"Med (Baltim)"},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905\u201312.","journal-title":"Endocr J"},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.13532","volume":"44","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, et al. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017;44:e13\u20134.","journal-title":"J Dermatol"},{"key":"1384_CR12","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.13571","volume":"44","author":"A Narahira","year":"2017","unstructured":"Narahira A, Yanagi T, Cho KY, et al. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol. 2017;44:e70.","journal-title":"J Dermatol"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/1346-8138.13437","volume":"44","author":"M Ishikawa","year":"2017","unstructured":"Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017;44:109\u201310.","journal-title":"J Dermatol"},{"key":"1384_CR14","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","volume":"56","author":"K Takaya","year":"2017","unstructured":"Takaya K, Sonoda M, Fuchigami A, et al. Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Intern Med. 2017;56:2463\u20139.","journal-title":"Intern Med"},{"key":"1384_CR15","first-page":"115","volume":"42","author":"T Seki","year":"2017","unstructured":"Seki T, Yasuda A, Oki M, et al. Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma. Tokai J Exp Clin Med. 2017;42:115\u201320.","journal-title":"Tokai J Exp Clin Med"},{"key":"1384_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyx018","volume":"47","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Ashida K, Wada N, et al. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol. 2017;47:463\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","volume":"57","author":"N Ohara","year":"2018","unstructured":"Ohara N, Ohashi K, Fujisaki T, et al. Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review. Intern Med. 2018;57:527\u201335.","journal-title":"Intern Med"},{"key":"1384_CR18","first-page":"285","volume":"80","author":"Y Tsukizawa","year":"2018","unstructured":"Tsukizawa Y, Kondo K, Ichiba T, et al. Refractory hypotension due to Nivolumab-induced adrenal insufficiency. Nagoya J Med Sci. 2018;80:285\u20138.","journal-title":"Nagoya J Med Sci"},{"key":"1384_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2340\/00015555-2902","volume":"98","author":"S Kitano","year":"2018","unstructured":"Kitano S, Tatsuno K, Ishibe J, et al. Isolated adrenocorticotropic hormone deficiency in melanoma patients treated with nivolumab. Acta Derm Venereol. 2018;98:704\u20135.","journal-title":"Acta Derm Venereol"},{"key":"1384_CR20","first-page":"18","volume":"48","author":"S Shrotriya","year":"2018","unstructured":"Shrotriya S, Rai MP, Alratroot A, et al. Delayed presentation of isolated adrenocorticotropin insufficiency after nivolumab therapy for advanced non-small-cell lung carcinoma (NSCLC). BMJ Case Rep. 2018;48:18.","journal-title":"BMJ Case Rep"},{"key":"1384_CR21","first-page":"223","volume":"26","author":"Y Sato","year":"2019","unstructured":"Sato Y, Tanaka Y, Hino M, et al. A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. Respir Med Case Rep. 2019;26:223\u20136.","journal-title":"Respir Med Case Rep"},{"key":"1384_CR22","first-page":"304","volume":"10","author":"N Furubayashi","year":"2019","unstructured":"Furubayashi N, Negishi T, Uozumi T, et al. Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: a case report. Mol Clin Oncol. 2019;10:304\u20138.","journal-title":"Mol Clin Oncol"},{"key":"1384_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","volume":"19","author":"A Takeno","year":"2019","unstructured":"Takeno A, Yamamoto M, Morita M, et al. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. BMC Endocr Disord. 2019;19:25.","journal-title":"BMC Endocr Disord"},{"key":"1384_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1507\/endocrj.EJ19-0076","volume":"66","author":"T Sekizaki","year":"2019","unstructured":"Sekizaki T, Kameda H, Oba C, et al. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. Endocr J. 2019;66:937\u201341.","journal-title":"Endocr J"},{"key":"1384_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2169\/internalmedicine.1268-18","volume":"58","author":"Y Mishima","year":"2019","unstructured":"Mishima Y, Fukaishi T, Inase N, et al. Nivolumab-induced hypophysitis, secondary adrenal insufficiency and destructive thyroiditis in a patient with lung adenocarcinoma. Intern Med. 2019;58:693\u20137.","journal-title":"Intern Med"},{"key":"1384_CR26","doi-asserted-by":"publisher","first-page":"e231236","DOI":"10.1136\/bcr-2019-231236","volume":"12","author":"C Martins Machado","year":"2019","unstructured":"Martins Machado C, Almeida Santos L, Barroso A, et al. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. BMJ Case Rep. 2019;12:e231236.","journal-title":"BMJ Case Rep"},{"key":"1384_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","volume":"13","author":"N Ohara","year":"2019","unstructured":"Ohara N, Kobayashi M, Ohashi K, et al. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. J Med Case Rep. 2019;13:88.","journal-title":"J Med Case Rep"},{"key":"1384_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, et al. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment. Endocr J. 2017;64:235\u20136.","journal-title":"Endocr J"},{"key":"1384_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382.","journal-title":"JAMA Oncol"},{"key":"1384_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40792-018-0479-3","volume":"4","author":"T Namikawa","year":"2018","unstructured":"Namikawa T, Ishida N, Tsuda S, et al. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep. 2018;4:71.","journal-title":"Surg Case Rep"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01384-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T16:22:02Z","timestamp":1626970922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,14]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01384-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,14]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tsutomu Namikawa, Shigeto Shimizu, Keiichiro Yokota, Nobuhisa Tanioka, Ian Fukudome, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa, and Kazuhiro Hanazaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}